At a glance
- Originator Eisai Co Ltd
- Class Antihypertensives; Quinazolines; Small molecules
- Mechanism of Action Cyclic GMP phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary spasm
Most Recent Events
- 04 Oct 1995 Preclinical development for Coronary spasm in Japan (Unknown route)
- 21 Aug 1995 Preclinical development for Ischaemic heart disorders in Japan (Unknown route)